Verona PharmaVRNA Market cap $2.6B
About: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Employees: 79
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
39% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 31
11% more funds holding
Funds holding: 111 [Q1] → 123 (+12) [Q2]
3% more call options, than puts
Call options by funds: $10.8M | Put options by funds: $10.5M
0.63% more ownership
Funds ownership: 10.33% [Q1] → 10.96% (+0.63%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]
12% less capital invested
Capital invested by funds: $1.08B [Q1] → $952M (-$132M) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Wells Fargo Tiago Fauth 93% 1-year accuracy 13 / 14 met price target | 56%upside $50 | Overweight Initiated | 3 Oct 2024 |
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 113 / 288 met price target | 12%upside $36 | Buy Reiterated | 1 Oct 2024 |
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 113 / 288 met price target | 12%upside $36 | Buy Reiterated | 17 Sept 2024 |
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 113 / 288 met price target | 12%upside $36 | Buy Reiterated | 11 Sept 2024 |
Canaccord Genuity Edward Nash 50% 1-year accuracy 9 / 18 met price target | 16%upside $37 | Buy Maintained | 22 Jul 2024 |